Jiwon Oh, AAN 2021: Fenebrutinib in Multiple Sclerosis
Dr Jiwon Oh (University of Toronto, Canada) caught up with touchNEUROLOGY to discuss investigating fenebrutinib as a potential Multiple Sclerosis therapy.
The abstract entitled: ‘The Safety of Fenebrutinib in a Large Population of Patients With Diverse Autoimmune Indications Supports Investigation in Multiple Sclerosis (MS)’ was presented at the American Academy of Neurology Virtual Annual Meeting 2021.
- What is the rationale for the use of BTK inhibitors in MS? (0:14)
- How does fenebrutinib differ from other agents in its class in terms of suitability as an MS therapy? (1:20)
- What autoimmune indications were included in your safety analysis? (3:41)
- What were the findings of this analysis? (4:30)
- What were the conclusions in terms of potential use at high doses in MS patients? (6:51)
Jiwon Oh has received personal compensation for consulting or speaking from EMD-Serono, Sanofi-Genzyme, Biogen-Idec, Novartis, BMS, and Roche, and has received research funding from the MS Society of Canada, the National MS Society, Brain Canada, Biogen-Idec, Roche, and EMD-Serono.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of AAN Annual Virtual Meeting 2021.
Share this Video
Related Videos In Multiple Sclerosis
Barry Singer, ECTRIMS 2022: Diroximel fumarate for relapsing-remitting multiple sclerosis – Phase 3 results from EVOLVE-MS-1
The phase 3 EVOLVE-MS-1 (NCT02634307), was a 96-week, open-label, Phase 3 study, assessing safety, tolerability, and exploratory clinical and MRI efficacy of diroximel fumarate in adults with relapsing-remitting multiple sclerosis (RRMS). Diroximel fumarate, an oral fumarate for relapsing-remitting multiple sclerosis, has the same active metabolite as dimethyl fumarate. Diroximel fumarate has similar efficacy and safety […]
Barry Singer, ECTRIMS 2022: Flushing and GI adverse events in RRMS patients on diroximel fumarate – Analysis from phase 3 EVOLVE-MS-1 study
The phase 3 EVOLVE-MS-1 (NCT02634307), was a 96-week, open-label, Phase 3 study, assessing safety, tolerability, and exploratory clinical and MRI efficacy of diroximel fumarate in adults with relapsing-remitting multiple sclerosis (RRMS). Diroximel fumarate, an oral fumarate for relapsing-remitting multiple sclerosis, has the same active metabolite, and similar efficacy and safety to dimethyl fumarate but with […]
Dominic Shadbolt: ECTRIMS Patient perspective – Lifestyle interventions as part of a management plan for MS
We welcome Dominic Shadbolt, a patient advocate in multiple sclerosis (MS), and founder of theMSguide.com. Dominic joins touchNEUROLOGY to share his perspective on being a patient advocate at the annual ECTRIMS congress, and highlights from the most salient presentations. In this interview, Dominic highlights the lifestyle interventions that people living with MS can undertake as […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!